Two Sigma Investments LP Grows Stake in Sucampo Pharmaceuticals, Inc. (SCMP)

Two Sigma Investments LP grew its holdings in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 1,013.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 548,672 shares of the biopharmaceutical company’s stock after purchasing an additional 499,409 shares during the quarter. Two Sigma Investments LP’s holdings in Sucampo Pharmaceuticals were worth $9,849,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SCMP. Northern Trust Corp increased its position in shares of Sucampo Pharmaceuticals by 12.4% during the 2nd quarter. Northern Trust Corp now owns 343,167 shares of the biopharmaceutical company’s stock valued at $3,603,000 after purchasing an additional 37,749 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Sucampo Pharmaceuticals by 63.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 55,552 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 21,641 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of Sucampo Pharmaceuticals by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 13,411 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 2,477 shares during the period. State Street Corp grew its stake in shares of Sucampo Pharmaceuticals by 7.3% during the 2nd quarter. State Street Corp now owns 599,420 shares of the biopharmaceutical company’s stock valued at $6,290,000 after acquiring an additional 40,929 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Sucampo Pharmaceuticals by 4.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 790 shares during the period. 67.09% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at $18.05 on Tuesday. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The firm has a market capitalization of $839.46, a P/E ratio of -5.37, a price-to-earnings-growth ratio of 5.06 and a beta of 1.38.

A number of brokerages recently issued reports on SCMP. BidaskClub downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 14th. Zacks Investment Research downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Nomura reiterated a “neutral” rating and set a $18.00 price objective on shares of Sucampo Pharmaceuticals in a research note on Friday, January 26th. Finally, UBS downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price objective for the company. in a research note on Friday, January 5th. Eight investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $20.73.

TRADEMARK VIOLATION WARNING: “Two Sigma Investments LP Grows Stake in Sucampo Pharmaceuticals, Inc. (SCMP)” was reported by Stock Observer and is owned by of Stock Observer. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.thestockobserver.com/2018/03/20/two-sigma-investments-lp-grows-stake-in-sucampo-pharmaceuticals-inc-scmp.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply